No Data
No Data
Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
Express News | Pasithea Therapeutics Corp: Remain on Track to Present Our Initial Safety and Pharmacokinetic (Pk) Data in Q3 of 2024.
Express News | Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Pas-004 in Ongoing Phase 1 Clinical Trial
12 Health Care Stocks Moving In Tuesday's Intraday Session
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
10-Q: Quarterly report
No Data